Evidence map›Paper›PMID 38245794›Full record

ArticleMolecular neurodegeneration2024

Unravelling cell type-specific responses to Parkinson's Disease at single cell resolution.

Araks Martirosyan, Rizwan Ansari, Francisco Pestana, Katja Hebestreit, Hayk Gasparyan, Razmik Aleksanyan, Silvia Hnatova, Suresh Poovathingal, Catherine Marneffe, Dietmar R Thal and 7 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Araks Martirosyan *VIB Center for Brain & Disease Research, KU Leuven, Leuven, Belgium.
Rizwan Ansari *UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK.
Francisco Pestana *VIB Center for Brain & Disease Research, KU Leuven, Leuven, Belgium.
Katja HebestreitVerge Genomics, South San Francisco, CA, USA.
Hayk GasparyanArmenian Bioinformatics Institute, Yerevan, Armenia.
Razmik AleksanyanArmenian Bioinformatics Institute, Yerevan, Armenia.
Silvia HnatovaUK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK.
Suresh PoovathingalVIB Center for Brain & Disease Research, KU Leuven, Leuven, Belgium.
Catherine MarneffeVIB Center for Brain & Disease Research, KU Leuven, Leuven, Belgium.
Dietmar R ThalLaboratory for Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, and Department of Pathology, UZ Leuven, Leuven, Belgium.
Andrew KottickVerge Genomics, South San Francisco, CA, USA.
Victor J Hanson-SmithVerge Genomics, South San Francisco, CA, USA.
Sebastian GuelfiVerge Genomics, South San Francisco, CA, USA.
William PlumblyUK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK.
T Grant BelgardThe Bioinformatics CRO, Orlando, FL, USA.
Emmanouil MetzakopianUK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK. manos.metzakopian@bit.bio.ORCID 0000-0003-2893-9741
Matthew G HoltVIB Center for Brain & Disease Research, KU Leuven, Leuven, Belgium. mholt@i3s.up.pt.ORCID 0000-0002-8958-4027
VIB-KU Leuven Center for Brain & Disease Research · BEUniversity of Cambridge · GBYerevan State University · AMBabraham Institute · GBOrlando Immunology Center · USUniversidade do Porto · PTUniversitair Ziekenhuis Leuven · BE

Funding

Bit Bio Ltd RRAG/257European Commission 951923European Commission H2020 WIDESPREAD-2018-2020-6European Commission NCBioFonds Wetenschappelijk Onderzoek G065721NFonds Wetenschappelijk Onderzoek G0F8516NFundação para a Ciência e a Tecnologia 2020.08750BDKU-Leuven Internal Funding C14/17/107KU-Leuven Internal Funding C14/22/132KU-Leuven Internal Funding C3/20/057Open Targets OTAR2052Stichting Alzheimer Onderzoek 20200034Stichting Alzheimer Onderzoek 2020/017UK Dementia Research Institute RRZA/175Welcome Trust RG86251
6 · The paper itself

Abstract

Parkinson's Disease (PD) is the second most common neurodegenerative disorder. The pathological hallmark of PD is loss of dopaminergic neurons and the presence of aggregated α-synuclein, primarily in the substantia nigra pars compacta (SNpc) of the midbrain. However, the molecular mechanisms that underlie the pathology in different cell types is not currently understood. Here, we present a single nucleus transcriptome analysis of human post-mortem SNpc obtained from 15 sporadic Parkinson's Disease (PD) cases and 14 Controls. Our dataset comprises ∼84K nuclei, representing all major cell types of the brain, allowing us to obtain a transcriptome-level characterization of these cell types. Importantly, we identify multiple subpopulations for each cell type and describe specific gene sets that provide insights into the differing roles of these subpopulations. Our findings reveal a significant decrease in neuronal cells in PD samples, accompanied by an increase in glial cells and T cells. Subpopulation analyses demonstrate a significant depletion of tyrosine hydroxylase (TH) enriched astrocyte, microglia and oligodendrocyte populations in PD samples, as well as TH enriched neurons, which are also depleted. Moreover, marker gene analysis of the depleted subpopulations identified 28 overlapping genes, including those associated with dopamine metabolism (e.g., ALDH1A1, SLC6A3 & SLC18A2). Overall, our study provides a valuable resource for understanding the molecular mechanisms involved in dopaminergic neuron degeneration and glial responses in PD, highlighting the existence of novel subpopulations and cell type-specific gene sets.

Indexed as

Parkinson DiseaseDopaminergic NeuronsHumansMesencephalonSubstantia Nigra

Identifiers

PMID38245794
PMCPMC10799528
OpenAlexW4391053007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.